Compare Monolithic Power Systems Inc (MPWR) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Monolithic Power Systems Inc vs Neurocrine Biosciences Inc — how do they compare? Monolithic Power Systems Inc trades at $1,383 (market cap $65.28B), while Neurocrine Biosciences Inc trades at $179 (market cap $17.40B). The key difference: Monolithic Power Systems Inc is far larger — about 3.8× Neurocrine Biosciences Inc's market cap, and Monolithic Power Systems Inc pays a 0.6% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| MPWR | NBIX | |
|---|---|---|
Market Cap | $65.28B | $17.40B |
Sector | Utilities | Health |
52-Week High | $1.69K | $180.55 |
52-Week Low | $711.24 | $123.10 |
Enterprise Value | $63.94B | $16.49B |
Dividend Yield | 0.6% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Monolithic Power Systems Inc
Monolithic Power Systems, Inc. is a global leader in high-performance, analog, and mixed-signal semiconductors. The company specializes in power management solutions, providing integrated circuits (ICs) for a wide range of applications, including computing, automotive, industrial, and communications. MPWR's proprietary process technology is designed to deliver highly energy-efficient and compact power solutions, positioning the company as a key supplier for the next generation of electronic devices.
Read more on MPWR →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
